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Introduction: Worldwide, diabetes mellitus presents a high burden for individuals and society. 
In Latin America, many people with diabetes have limited access to health care, which means that 
indirect costs may exceed direct health care cost. Diabetes is Mexico’s leading cause of death.
Purpose: To evaluate the cost-effectiveness ratios of the most used oral hypoglycemic agents 
(OHA) in the treatment of outpatients with type 2 diabetes attending a public primary care 
clinic in Mexico City.
Design: A cross-sectional and analytic study was conducted in Mexico City.
Methodology: Twenty-seven adult outpatients with type 2 diabetes who were treated either 
with metformin or glibenclamide were included. Acarbose was used as an alternative strategy. 
The study was carried out from the perspective of Mexican society. Direct medical and nonmedi-
cal costs as well as indirect costs were evaluated using a structured questionnaire. Efficacies 
of all drug treatments were evaluated retrospectively. A systematic search was conducted to 
select published randomized clinical trials based on predetermined inclusion criteria, and treat-
ment success was defined as glycosylated hemoglobin factor # 7%. Efficacy data of each drug 
and/or combination were analyzed using meta-analysis. The Monte Carlo Markov model was 
used. Quality-adjusted life-years (QALY) were used as the unit of effectiveness; incremental 
and sensitive analyses were performed and a 5% discount rate was calculated. A hypothetical 
cohort of 10,000 patients was modeled.
Results: The odds ratios of the success of each drug treatment were obtained from the meta-
analyses, and were the following: 5.82 (glibenclamide), 3.86 (metformin), 3.5 (acarbose), and 
6.76 (metformin–glibenclamide). The cost-effectiveness ratios found were US$272.63/QALY 
(glibenclamide), US$296.48/QALY (metformin), and US$409.86/QALY (acarbose). Sensitiv-
ity analysis did not show changes for the most cost-effective therapy when the effectiveness 
probabilities or treatment costs were modified.
Conclusion: Glibenclamide is the most cost-effective treatment for the present study outpatient 
population diagnosed with type 2 diabetes in the early stages.
Keywords: cost-effectiveness, hypoglycemic, outpatients, type 2 diabetes
Introduction
Worldwide, diabetes mellitus has been recognized as the greatest challenge for all 
health care systems.1 The care of diabetes presents a high burden for individuals and 
society. People with diabetes are at increased risk of macrovascular and microvas-
cular complications and are more likely than people without diabetes to have other 
  cardiovascular problems.2 In Latin America, many people with diabetes have limited 
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access to health care, which means that indirect costs may 
exceed direct health care cost.3   Diabetes is also impover-
ishing families at the household level.   According to the 
International Diabetes Federation (IDF), families in Latin 
America pay 40%–60% of the cost of diabetes care from 
their own pockets.4
Diabetes is Mexico’s leading cause of death. It is one of 
the most common chronic diseases, with a high prevalence 
and a growing epidemiologic trend. The IDF estimates that 
type 2 diabetes in Mexico had a prevalence of 10.8% in 
2010 and a projection of 13.3% for 2030.5 In Mexico, type 
2 diabetes is one of the main causes of premature disability, 
blindness, end-stage renal insufficiency, and nontraumatic 
amputation. Diabetes mellitus and ischemic cardiopathy have 
been the two main causes of mortality since 2000.6–8
In 2010, the total cost of diabetes in Mexico was estimated 
to be US$778.5 million, including US$343.2 million in 
direct costs and US$435.2 million in indirect costs.   Medical 
consultations, laboratory tests, drug costs, hospitalizations, 
and long-term diabetes-related complications are the most 
common direct costs implicated in diabetes treatment. 
  Permanent and temporary disabilities make up the most 
common indirect costs.9
The public health sector in Mexico is composed of several 
institutions: the Mexican Institute of Social Security (IMSS 
in Spanish), the Institute of Social Security in the Service to 
the State Workers, the Ministry of Health, health institutes, 
and others. Fifty-eight percent of the Mexican population is 
affiliated to the IMSS (the largest public health institution).10 
It provides most of the hospitals, clinics, and health centers 
to Mexican consumers. Nevertheless, there are an increasing 
number of Mexicans who are uninsured.
The public health sector has an essential drug list called 
the “Cuadro Básico y Catálogo de Medicamentos” and its use 
is compulsory for the entire sector. At present, six oral hypo-
glycemic agents (OHAs) are included in the Cuadro Básico 
y Catálogo de Medicamentos: metformin, glibenclamide, 
acarbose, rosiglitazone, pioglitazone, and sitagliptin.11,12 
Metformin, glibenclamide, and acarbose are most frequently 
used in primary care clinics for the pharmacological treat-
ment of type 2 diabetes. The efficacies of these OHAs and the 
direct acquisition costs of each varies. The Mexican health 
care systems dedicate substantial resources to the acquisi-
tion of OHAs to treat diabetes and associated risk factors but 
there are few indicators of their effectiveness.1 All drugs are 
provided free of charge to all insured patients.
As diabetes prevalence and incidence rates in Mexico are 
increasing rapidly, along with the high economic burden of 
its complications, it is very important to conduct a complete 
economic evaluation on diabetes treatments to optimize 
economic resources and contribute to a better quality of life 
for patients with diabetes.7 However, very few economic 
evaluations have been conducted in Mexico, particularly on 
type 2 diabetes.9 Studies about total costs are important, but 
complete economic evaluations are needed to make evidence-
based health decisions and, consequently, the best risk and 
cost-effective treatment choices.
The available information suggests ineffective perfor-
mance of the health care systems.1 Outpatients are facing 
difficulties in properly controlling their blood glucose levels 
due to lack of economic resources, for example, to acquire 
blood sugar meters as the public health care systems provide 
the drugs but not the devices.
Our study was designed to estimate the resource use and 
expenditure for diabetes in Mexican outpatients. A cost-
effectiveness (CE) analysis was carried out from the perspec-
tive of Mexican society in order to determine the monetary 
costs per unit of effectiveness of each selected OHA.
Methods
This research was carried out in an IMSS primary care 
clinic in Mexico City. The population sample included 
outpatients .18 years of age with type 2 diabetes diagnosed 
within the 2 years prior to initiation of the present study. Due 
to the early stage of the disease, we assumed that patients did 
not have any diabetes complications. The study was carried 
out from the perspective of Mexican society (public health 
sector). A 1-year time horizon was considered.
Model structure
A Markov model13 was designed and built to simulate the 
economic and health outcomes of treatment with OHAs 
(metformin and glibenclamide; acarbose was used as an 
alternative strategy) in a hypothetical cohort of 10,000 
patients whose type 2 diabetes was diagnosed within the 
2 years before the initiation of the present study. Different 
national and international therapeutic guidelines for the 
treatment of type 2 diabetes were revised and used in order 
to build the Markov model.14–18
Figure 1 shows the designed Markov model. Two health 
states were established defined by the glycosylated hemo-
globin (HbA1c) factor: (1) patients with no glycemic control 
(HbA1c .7.0%) and (2) patients with glycemic control   
(HbA1c #7.0%). A unidirectional transition from the 
first health state to the second, the probability of which 
  corresponds to treatment success, was considered. The 
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1-year time horizon was divided into 12 cycles of 1 month 
each: six cycles of first-line therapy and six cycles of rescue 
therapy with dual therapy used in cases of metformin or 
glibenclamide monotherapy (glibenclamide addition to the 
metformin or vice versa) failure; in the case of acarbose 
failure, addition of another pharmacological agent was not 
considered. In each health state, we assessed the presence 
or absence of primary nonserious adverse events (NSAEs) 
associated with treatment using the evaluated OHAs.
Transition probabilities
A systematic search of clinical trials in the medical 
literature was conducted for 1980–2009. The electronic 
databases consulted included PubMed,19 Scopus,20 Cochrane 
Library,21 and Medline.22 The search words (individually 
or in combination) were as follows: diabetes, diabetes 
mellitus, noninsulin-dependent diabetes mellitus, metformin, 
glibenclamide, acarbose, and clinical trial. Inclusion criteria 
for the clinical tests’ selection were the following: double-
blind, randomized, and placebo-controlled trials (except in 
the cases of dual therapy); adult patients with type 2 diabetes 
(without gender distinction), with an average HbA1c #9%, 
and with an average body mass index #30 kg/m2; and final 
HbA1c levels reported in the study.
A value of HbA1c #7.0% was considered treatment 
success. Efficacy data of the HbA1c level reduction gath-
ered from the medical literature were analyzed by meta-
analysis. Revman Manager 5.0.24 software (The Cochrane   
Collaboration, Copenhagen, Denmark) was used to perform 
the meta-analysis and to obtain odds ratios (ORs) within a 
95% confidence interval (95% CI) for each treatment strat-
egy. An aleatory effects model was considered. The success 
probability of each therapeutic alternative was calculated 
from the OR data.
The occurrence probabilities of NSAEs associated to the 
OHA treatments were gathered from the selected clinical trial 
and published studies by The Cochrane Library.
Costs
Direct medical costs included medical care costs, laboratory 
tests, and the acquisition drug costs in 2009, which were 
investigated through the national Federal Official Daily 
Gazette publication and the IMSS 2009 bidding drug results 
published at its website (drug costs).23,24 In the Mexican public 
health system, drugs and health services are given free of 
charge to all insured members of the population.
Four medical visits, four laboratory tests per patient, and 
administration of the maximum tolerated doses of each drug 
were assumed. Nonmedical direct costs (transportation) and 
indirect costs (lost working time or days) were evaluated 
through a structured questionnaire given to 27 patients 
with type 2 diabetes who were affiliated with the IMSS 
primary care clinic and who were receiving metformin, 
glibenclamide, or the metformin-glibenclamide combination. 
Acarbose treatment was included based on the national 
guidelines, but none of the 27 patients were treated with 
acarbose. The metformin (850 mg/tablet), glibenclamide 
(5 mg/tablet), and acarbose (50 mg/tablet) monotherapies 
maximum daily defined doses were 2550 mg (three tablets), 
20 mg (four tablets), and 300 mg (six tablets) respectively. 
The metformin-glibenclamide combination maximum daily 
defined dose was 1700 mg (two tablets) of metformin and 
15 mg (3 tablets) of glibenclamide. The drug costs per each 
tablet are the following:24 metformin $0.0098, glibenclamide 
$0.0032, and acarbose $0.0317. All costs were calculated in 
US dollars. The US dollar exchange rate to Mexican pesos 
was US$1 = MXN$13.35 (January 2009).
All patients gave informed consent before answering the 
cost questionnaire and their confidentiality was respected.
To calculate the costs associated with lost working time, 
the minimum wage prevailing in Mexico City in 2010 was 
assumed ($4.1 per day).25
Cost-effectiveness analysis
The TreeAge® Pro Suite 2009 (TreeAge Software Inc, 
  Williamstown, MA) software was used to program the 
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Monte Carlo Markov model designed as a decision tree. 
The treatment success probabilities obtained from the 
meta-analysis of each OHA were used. Monthly costs of 
therapeutic alternatives were employed in the model. The 
health outcomes obtained were quantified in terms of quality-
adjusted life-years (QALY). A hypothetical cohort of 10,000 
patients was considered in order to obtain the CE ratio of 
each therapeutic alternative as well as the final proportions 
of patients with treatment success or failure and the presence 
of NSAEs. Univariate sensitivity analysis was carried out to 
evaluate the effect of the parameter uncertainty evaluated on 
the CE ratios obtained. The annual total costs varied by ±25%, 
and the confidence interval of the OR obtained from the meta-
analysis was used for this purpose. An incremental CE ratio 
(ICER) analysis of the dominant treatments in relation to 
the most cost-effective treatment was performed. Updated 
annual costs of each treatment were determined assuming a 
5% discount rate and 5 years into the future.
Results
Transition probabilities
To determine the efficacy of each drug evaluated in this study, 
clinical trials were selected according to inclusion criteria. 
As a result of the scientific literature systematic review, 
four clinical trials were selected that included a total of 766 
patients for the metformin group and 496 patients in the 
placebo group.26–29 Two clinical trials meeting the inclusion 
criteria for glibenclamide included a total of 188 patients in 
the treatment group and 186 in the treatment group.28–30 For 
treatment with acarbose, two clinical trials were selected that 
included a total of 90 patients in the treatment group and 
88 patients in the placebo group.30,32
When glibenclamide or metformin treatment failed, the 
recommendations of the therapeutic guidelines were used 
in order to choose the second-line treatment. Therapeutic 
guidelines recommend the addition of glibenclamide 
after therapeutic failure of metformin and vice versa. 
In the case of metformin failure, the only clinical trial 
meeting the inclusion criteria included 103 patients in 
whom glibenclamide was added to the initial monotherapy 
(metformin + glibenclamide) and 104 patients who continued 
metformin monotherapy (control group).32 The 2 clinical 
trials selected for glibenclamide failure included 350 patients 
in whom metformin was added to the initial monotherapy 
(glibenclamide + metformin) and 341 patients who continued 
glibenclamide monotherapy (control group).26,33
The final HbA1c outcomes of each treatment reported in the 
selected clinical trial were analyzed by meta-analysis except 
for the metformin + glibenclamide combination since only 
one study was considered. Table 1 shows the meta-analysis 
outcomes. The ORs with 95% confidence intervals are as 
follows: 3.86 (2.72–5.47) for metformin (Table 1A), 5.82 
(3.54–9.56) for glibenclamide (Table 1B), 3.50 (1.52–8.03) 
for acarbose (Table 1C), and 6.76 (4.38–10.46) for glib-
enclamide + metformin combination therapy (Table 1D). 
Table 1 does not show the outcome of the metformin + 
glibenclamide combined therapy, but a 2.88 (1.63–5.09) OR 
was obtained. The OR values were transformed to treatment 
success probabilities and 0.2315, 0.2582, and 0.2217 were 
obtained for monotherapy with metformin, glibenclamide, 
and acarbose, respectively. The probabilities of the dual 
therapies were 0.2022 for glibenclamide + metformin and 
0.2893 for metformin + glibenclamide.
Regarding the NSAEs, the following frequencies were 
seen: metformin-associated gastrointestinal problems, 53.9%; 
glibenclamide-related gastrointestinal and hypoglycemia 
problems, 27.6%; acarbose-related gastrointestinal problems, 
77.6%; and metformin + glibenclamide combination-related 
gastrointestinal plus hypoglycemia problems, 52.4%.32–35
Costs
Direct medical costs were US$154.90 for medical visits and 
US$21.57 for laboratory tests for the three OHA and the 
metformin + glibenclamide combination. The annual drug 
costs were calculated as follows: metformin, US$10.74; 
glibenclamide, US$4.61; acarbose, $69.44; and metformin + 
glibenclamide combination, US$10.62. With regard to trans-
portation cost (nonmedical direct cost), an average cost of 
US$5.03 for metformin, US$6.44 for glibenclamide, and 
US$22.92 for the metformin + glibenclamide combination 
was   calculated. With regard to indirect costs, none of the 
persons interviewed declared losing a complete working day, 
only working hours. The lost income cost was as follows: 
US$0.47 for metformin, US$0.58 for glibenclamide, and 
US$0.06 for the metformin + glibenclamide combination. In 
general, the lost working time cost was low because patients 
had a diagnosis of type 2 diabetes ,2 years prior and had not 
yet experienced severe disease-related complications.
The total annual costs per OHA per patient were as fol-
lows: metformin, US$192.71; glibenclamide, US$188.10; 
acarbose, US$245.91; and metformin + glibenclamide 
combination, US$210.07.
Cost-effectiveness analysis
Figure 2 shows the design of the Monte Carlo Markov cycles 
decision tree. The tree was programmed with the transition 
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probabilities obtained from the meta-analysis as well as with 
the monthly estimated costs of each therapeutic   alternative. 
The CE ratios were as follows: metformin, US$296.48/
QALY; glibenclamide, US$272.63/QALY; and acarbose, 
US$409.86/QALY. The NSAE frequencies were as follows: 
metformin, 53.6% (gastrointestinal); glibenclamide, 31.3% 
(gastrointestinal/hypoglycemia); and acarbose, 77.6% 
(gastrointestinal).
Sensitivity analysis
Figure 3A–C shows the univariate sensitivity analyses of 
the evaluated treatment alternatives. It can be observed 
that glibenclamide is the dominant therapy over metformin 
and acarbose. When the monthly treatment costs varied 
(Figure 3A), the glibenclamide CE ratio remained the most 
cost-effective therapy. When the monotherapy success 
probability varied (Figure 3B), the glibenclamide CE 
ratio remained the most cost-effective therapy. When the 
metformin + glibenclamide combination therapy success 
probability (Figure 3C) varied, no CE ratio variation was 
observed. In short, glibenclamide + metformin dual therapy 
was more cost-effective than metformin + glibenclamide 
treatment.
incremental analysis and discount rate
The outcome of the ICER for glibenclamide versus met-
formin was US$114.83/QALY, while that for glibenclamide 
versus acarbose was US$642.19/QALY. The update to 5 
years’ use of glibenclamide, the most cost-effective treat-
ment, was US$146.85.
Discussion
Glibenclamide was the most cost-effective treatment for 
patients whose type 2 diabetes had been diagnosed in the 
early stages.
Direct medical costs for type 2 diabetes patients are high, 
representing a high economic burden for health institutions 
like IMSS that provide these services and drugs.1 Out-of-
pocket type 2 diabetes treatments for patients represent a 
high economic burden for the uninsured population as well 
as for the insured one.2 The situation is more serious when it 
comes to patients who earn the minimum wage, as the average 
annual treatment cost is US$196.60 and represents 14.3% 
of the patient’s annual income (US$1,377.60).25
With regard to the efficacy of the evaluated therapeutic 
alternatives to control hyperglycemia levels, the meta-
  analysis showed that glibenclamide treatment is more 
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Figure 2 Markov model as a decision tree designed using the TreeAge® program.
Notes:  = the node of the decision to be made;  M = represents Markov nodes;  = random nodes (in the probabilities function);  = branch end finished in a health 
state. The hypothetical patient cohort begins with the health state characterized by HbA1c . 7%.
Abbreviations: HbA1c, glycosylated hemoglobin factor; NSAE, nonserious adverse event.
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  effective than metformin or acarbose treatment. With regard 
to the efficacy analysis of the metformin + glibenclamide 
combination, metformin addition after glibenclamide mono-
therapy failure showed higher efficacy than glibenclamide 
addition after metformin monotherapy failure.
The present study might give policy decision makers 
important information about how to allocate the necessary 
resources for diabetes and to meet the increasing demand for 
diabetes treatments. Long-term costs can be reduced when the 
right treatment is chosen in the early stages of the disease.
Glibenclamide monotherapy was found to be the most 
cost-effective in the simulation model of a 10,000-patient 
hypothetical cohort. This may be the reason why it is the most 
commonly recommended option in the initial oral pharmaco-
logical treatment of patients with type 2 diabetes. However, 
according to the health outcomes observed metformin has a 
very close CE ratio and could be considered as the second 
choice. As acarbose resulted in the highest costs per unit of 
effectiveness, it is the least recommended treatment and could 
be used in the treatment of patients in whom glibenclamide 
or metformin treatment is contraindicated due to renal failure 
or other causes and/or in patients of advanced age.36,37
The ICER results showed that each QALY gained with 
metformin treatment is US$114.83 more expensive than that 
with glibenclamide treatment, whereas each QALY gained 
with acarbose treatment is US$642.19 more expensive than 
that with glibenclamide treatment. Metformin and acar-
bose treatments were the therapeutic options dominated by 
glibenclamide.
In the present study, the total direct nonmedical and 
indirect costs were lower than the total direct medical 
costs. In an earlier study on costs of type 2 diabetes conducted 
in the IMSS, the total direct and indirect nonmedical costs 
were higher than the total medical direct costs.10 However, 
the patients included in the present study were in the 
early stages of the disease and long-term diabetes-related 
complications were not yet present. In addition, patients 
were treated at a public primary care clinic and medical care 
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costs were lower than those of a highly specialized hospital. 
Moreover, diabetes is a degenerative chronic disease that 
requires treatment throughout a patient’s life span and causes 
prolonged work disability; such features might increase the 
direct nonmedical and indirect costs. These aspects might 
explain the differences in costs and in the CE analysis.
The results of our study are supported by the robustness 
of the model evaluated through univariate sensitivity analysis 
but we acknowledge a small population sample was used to 
calculate the treatment costs. In building this model, great 
effort was put into collecting updated, representative, and 
consistent information; therefore, the conclusions that can be 
drawn from it are valid and the probability of bias is small. 
The hypothetical cohort of 10,000 patients modeled was 
intended to soften the impact of the bias. Analytical models 
are generally used for that purpose.
Conclusion
Glibenclamide is the most cost-effective treatment for the 
present study outpatient population diagnosed with type 2 
diabetes in the early stages. Further similar investigations 
including a larger population sample are needed in order to 
draw definitive conclusions.
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